FDA Greenlights New Therapy for HER2-Positive Biliary Cancer
VANCOUVER – Zymeworks Inc . (NASDAQ:), a biotechnology firm specializing in biotherapeutics, has announced the U.S. Food and Drug Administration’s (FDA) accelerated approval of Ziihera (zanidatamab-hrii) for HER2-positive biliary tract…